Skip to main content
. Author manuscript; available in PMC: 2023 Dec 17.
Published in final edited form as: Ann Intern Med. 2015 Nov 24;163(12):899–907. doi: 10.7326/M15-0642

Table 1.

Baseline Demographic and Clinical Characteristics*

Characteristic Ledipasvir + Sofosbuvir + GS-9451 (n = 25) Ledipasvir + Sofosbuvir + GS-9451 + GS-9669 (n = 25)
Mean age (SD), y 54 (10) 58 (8)
Male 17 (68) 19 (76)
Race
 African American 19 (76) 19 (76)
 White 5 (20) 6 (24)
Ethnicity
 Hispanic 1 (4) 0 (0)
 Non-Hispanic 24 (96) 25 (100)
Mean BMI (SD), kg/m2 28 (5) 27 (5)
HCV genotype
 1a 18 (72) 16 (64)
 1b 7 (28) 9 (36)
HCV RNA level >6 × 106 IU/mL IFNL3/IL28B genotype 11 (44) 10 (40)
 CC 3 (12) 2 (8)
 CT 18 (72) 14 (56)
 TT 4 (16) 8 (32)
IFNL4 genotype
 TT/TT 2 (8) 1 (4)
 ΔG/TT 18 (72) 15 (60)
 ΔG/ΔG 5 (20) 8 (32)
Knodell HAI, METAVIR, or FibroSURE score§
 0 5 (20) 8 (32)
 1 14 (56) 12 (48)
 2 6 (24) 4 (16)
 3 0 (0) 1 (4)
Presence of any NS3, NS5A, or NS5B RAV 10 (40) 10 (40)
Presence of NS3, NS5A, or NS5B RAV with >20-fold resistance 3 (12) 7 (28)

BMI = body mass index; HAI = Histology Activity Index; HCV = hepatitis C virus; RAV = resistance-associated variant.

*

Values are numbers (percentages) unless otherwise indicated.

Self-reported.

Could not be typed in 1 patient.

§

In the 3-drug group, fibrosis staging was done with the FibroSURE test/aspartate aminotransferase–platelet ratio in 8 patients (32%), the Knodell HAI system in 15 patients (60%), and the METAVIR system in 2 patients (8%). In the 4-drug group, staging was done with the FibroSURE test/aspartate aminotransferase–platelet ratio in 5 patients (20%), the Knodell HAI system in 16 patients (64%), and the METAVIR system in 3 patients (12%). For fibrosis scores reported as a range, the maximum value in the range was used.

One patient with stage 2 fibrosis by the METAVIR system was considered eligible before enrollment but was deemed to have stage 3 fibrosis when the slide was reread at the National Institutes of Health using the Knodell HAI system.